# Mepolizumab in Episodic Angioedema With Eosinophilia

> **NCT04128371** · PHASE2 · TERMINATED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 5 (actual)

## Conditions studied

- Eosinophilia
- Angioedema

## Interventions

- **BIOLOGICAL:** mepolizumab

## Key facts

- **NCT ID:** NCT04128371
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-01-14
- **Primary completion:** 2022-10-31
- **Final completion:** 2022-10-31
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Study was closed after the first five participants completed their participation due to lack of efficacy.
- **Last updated:** 2024-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04128371

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04128371, "Mepolizumab in Episodic Angioedema With Eosinophilia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04128371. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*